To study the cellular consequences of cohesin mutations in myeloid malignancies, we used CRISPR/Cas9 to engineer a spectrum of predicted LOF STAG2, SMC3, and RAD21 mutations identified in patients in AML cell lines WT for all cohesin subunits and modulators. The gene discussed is SMC3; the disease is acute myeloid leukemia.